Action - AEN

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

Prix Achat

Prix Vente

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

Adeona Becomes Synthetic Biologics, Inc.

Adeona Becomes Synthetic Biologics, Inc. -- New Name Reflects Biotechnology Company Focus on the Emerging Field of Synthetic Biologics -- -- New...

Adeona CEO to Present at the Harvard Investors Group Forum

Adeona CEO to Present at the Harvard Investors Group Forum PR Newswire ANN ARBOR, Mich., Feb. 9, 2012 ANN ARBOR, Mich., Feb. 9, 2012 /PRNewswire/...

Adeona Appoints C. Evan Ballantyne as Chief Financial Officer

Adeona Appoints C. Evan Ballantyne as Chief Financial Officer -- Former CFO of Clinical Data, Inc. Brings Extensive Financial Background to...

Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biolo...

Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biologics Strategic...

Adeona Announces Initiation of Phase II Clinical Trial of Trimesta™ for Cognitive Dysfunction in Multiple Sclerosis

Adeona Announces Initiation of Phase II Clinical Trial of Trimesta™ for Cognitive Dysfunction in Multiple Sclerosis PR Newswire ANN ARBOR, Mich...

Adeona Announces Proposed Name Change to Synthetic Biologics, Inc., and Appointment of John Monahan, Ph.D., as Senior Vice Pr...

Adeona Announces Proposed Name Change to Synthetic Biologics, Inc., and Appointment of John Monahan, Ph.D., as Senior Vice President of Research...

Positive Clinical Study Results Reported by Adeona's Oral Zinc for ALS Collaborator

Positive Clinical Study Results Reported by Adeona's Oral Zinc for ALS Collaborator -- PNA Center for Neurological Research Clinical Study...

Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary ...

Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial...

Adeona Reports Third Quarter 2011 Financial Results

Adeona Reports Third Quarter 2011 Financial Results -- Clinical Trial for Cognitive Dysfunction in Multiple Sclerosis Recruiting Patients -- PR...

Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research

Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research PR Newswire ANN ARBOR, Mich., Nov. 11, 2011 ANN ARBOR...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

AEN - Frequently Asked Questions (FAQ)

What is the current share price?

The current share price of is US$ 0,00

What is the 1 year trading range for share price?

has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
CHROChannel Therapeutics Corporation	US$ 2,23 (25,28%)	74,35k
SOARVolato Group Inc	US$ 2,53 (19,34%)	571,74k
PWPower REIT	US$ 1,25 (15,74%)	489,14k
ETQT Rex 2X Inverse Ether Daily Target ETF	US$ 15,56 (13,20%)	6,94k
MWGMulti Ways Holdings Limited	US$ 0,3501 (13,08%)	442,11k
AEONAEON Biopharma Inc	US$ 1,41 (-70,99%)	4,6M
ATCHAtlasClear Holdings Inc	US$ 2,82 (-26,18%)	18,92M
PHGEBiomX Inc	US$ 0,7917 (-14,93%)	427,15k
AMBOAmbow Education Holding Ltd	US$ 2,11 (-14,57%)	42,76k
SGNSigning Day Sports Inc	US$ 1,89 (-12,90%)	129,23k
SPXSDirexion Daily S&P 500 Bear 3X Shares New	US$ 6,10 (0,00%)	95,9M
NVDQT Rex 2X Inverse NVIDIA Daily Target ETF	US$ 2,875 (-7,56%)	88,73M
TSLZT Rex 2X Inverse Tesla Daily Target ETF	US$ 4,14 (7,81%)	88,08M
SOXLDirexion Daily Semiconductor Bull 3X Shares	US$ 26,29 (4,87%)	75,87M
FXIiShares China Large Cap	US$ 36,455 (3,04%)	72,78M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Adeona Pharmaceuticals Common Stock (AEN)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

AEN Dernières nouvelles

Adeona Becomes Synthetic Biologics, Inc.

Adeona CEO to Present at the Harvard Investors Group Forum

Adeona Appoints C. Evan Ballantyne as Chief Financial Officer

Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biolo...

Adeona Announces Initiation of Phase II Clinical Trial of Trimesta™ for Cognitive Dysfunction in Multiple Sclerosis

Adeona Announces Proposed Name Change to Synthetic Biologics, Inc., and Appointment of John Monahan, Ph.D., as Senior Vice Pr...

Positive Clinical Study Results Reported by Adeona's Oral Zinc for ALS Collaborator

Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary ...

Adeona Reports Third Quarter 2011 Financial Results

Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research

AEN - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Adeona Pharmaceuticals Common Stock (AEN) Cours

Adeona Pharmaceuticals Common Stock (AEN)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

AEN Dernières nouvelles

Adeona Becomes Synthetic Biologics, Inc.

Adeona CEO to Present at the Harvard Investors Group Forum

Adeona Appoints C. Evan Ballantyne as Chief Financial Officer

Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biolo...

Adeona Announces Initiation of Phase II Clinical Trial of Trimesta™ for Cognitive Dysfunction in Multiple Sclerosis

Adeona Announces Proposed Name Change to Synthetic Biologics, Inc., and Appointment of John Monahan, Ph.D., as Senior Vice Pr...

Positive Clinical Study Results Reported by Adeona's Oral Zinc for ALS Collaborator

Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary ...

Adeona Reports Third Quarter 2011 Financial Results

Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research

AEN - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE